Alaproclate hydrochloride

Alaproclate was developed as one of the first selective serotonin reuptake inhibitor (SSRI) antidepressants by Astra AB (now AstraZeneca) in the 1970s. Development was discontinued due to concerns over hepatotoxicity observed in animal studies. Alaproclate is a selective serotonin reuptake inhibitor (SSRI) and inhibits depletion of a serotonin (5-HT) induced by 4-methyl-α-methyl-m-tyramine in rat cerebral cortex, hippocampus, hypothalamus and striatum. It has also been found to act as a non-competitive NMDA receptor antagonist although without discriminative stimulus properties similar to phencyclidine. Alaproclate inhibits NMDA-evoked currents and depolarization-induced voltage-dependent potassium currents in rat hippocampal neurons.

• Supplier: BOC Sciences
• Product #: 60719-83-7
• Cas: 60719-83-7
• Molecular Weight: 292.20
• Molecular Formula: C13H18ClNO2·HCl
• Canonical SMILES: Cl.CC(N)C(=O)OC(C)(C)CC1=CC=C(Cl)C=C1